<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02037204</url>
  </required_header>
  <id_info>
    <org_study_id>IMPACT</org_study_id>
    <nct_id>NCT02037204</nct_id>
  </id_info>
  <brief_title>IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Instant MSC Product Accompanying Autologous Chondron Transplantation (IMPACT): Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Articular cartilage defects in the knee have a poor intrinsic healing capacity and may lead
      to functional disability and osteoarthritis. Cartilage cell therapy using autologous
      chondrocyte implantation (ACI) has been established as the first advanced treatment therapy
      medicinal product. Although this technique has achieved good mid-term results, it is a costly
      and extensive two-stage procedure which is limited by the number of chondrocytes obtained by
      biopsy and the dedifferentiation resulting from the expansion phase. Therefore, there is a
      need for improvement. A new cartilage repair technique should aim at decreasing surgical
      trauma, lowering complexity, improving logistics and cost-effectiveness while retaining or
      improving clinical outcome. Direct contact between mesenchymal stromal cells (MSCs) and
      dedifferentiated articular chondrocytes in vitro showed improvement of the chondrogenic
      phenotype of dedifferentiated articular chondrocytes. In addition, preserving the
      pericellular matrix of chondrocytes improves cartilage formation. These chondrons
      (chondrocytes with their pericellular matrix) have shown improved cartilage formation when
      combined with allogeneic MSCs in extensive preclinical studies. The cells are mixed with
      fibrin cell carrier and applied to the cartilage lesion within one surgical procedure. This
      will reduce patient morbidity and improve patient care through immediate transplantation of a
      potent cell-based cartilage product. This is a phase I/II prospective monocenter study to
      evaluate the safety and feasibility of the IMPACT for treatment of focal articular cartilage
      lesions of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>First in man surgery: autologous chondrons are mixed with allogeneic MSCs and implanted in a fibrin glue carrier in a one-stage surgical procedure.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse Events</measure>
    <time_frame>18 months</time_frame>
    <description>Adverse events rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement, Knee Injury and Osteoarthritis Outcome Score</measure>
    <time_frame>3 and 18 months</time_frame>
    <description>Clinical improvement as measured by patient reported outcome scores. The questionnaire has been developed to evaluate the symptoms and limitations for patients with osteoarthritis. The outcome of the KOOS-scale varies from 0-100, where 0 indicates the greatest possible problems and is the worst outcome and 100 indicates no problems.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Structural Repair</measure>
    <time_frame>12 months</time_frame>
    <description>To examine parameters of structural repair at one year after treatment using MRI and a second-look arthroscopy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Care Use and Costs</measure>
    <time_frame>18 months</time_frame>
    <description>To assess the healthcare use and costs related to the procedure as well as the health-related work leave during the study period.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Foreign-Body Reaction</condition>
  <condition>Inflammation</condition>
  <condition>Effusion (L) Knee</condition>
  <condition>Knee Pain Swelling</condition>
  <arm_group>
    <arm_group_label>Cartilage repair surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cartilage repair surgery</intervention_name>
    <description>Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs</description>
    <arm_group_label>Cartilage repair surgery</arm_group_label>
    <other_name>Single-stage</other_name>
    <other_name>Cartilage repair</other_name>
    <other_name>IMPACT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 and &lt;45 years old

          -  Symptomatic isolated full-thickness articular cartilage lesion on the femoral condyle
             or trochlea.

          -  Size 2 - 8 cm2

          -  Intact anterior cruciate ligament

        Exclusion Criteria:

          -  (History of) osteoarthritis, defined as Kellgren-Lawrence grade &gt;3 as determined from
             appropriate X-ray.

          -  Concomitant inflammatory disease that affects the joint (rheumatoid arthritis,
             metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis)

          -  (History of) Septic arthritis.

          -  Malalignment requiring an osteotomy.

          -  (History of) total menisectomy in the target knee joint.

          -  Any surgery in the knee joint 6 months prior to study inclusion.

          -  Risk groups for MRI scanning due to the magnetic field like patients with pacemakers,
             nerve stimulators, metal particles, stents, clips or implants, (possible) pregnancy or
             breast feeding.

          -  Patients with severe anxiety for MRI scans and/or needles
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tommy S. de Windt, MD</last_name>
    <role>Study Director</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel B.F. Saris, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001570-29/NL</url>
    <description>Trials Register of the European Union</description>
  </link>
  <link>
    <url>https://www.youtube.com/watch?v=S3rIBjA03AA</url>
    <description>IMPACT animation</description>
  </link>
  <reference>
    <citation>Bekkers JE, Creemers LB, Tsuchida AI, van Rijen MH, Custers RJ, Dhert WJ, Saris DB. One-stage focal cartilage defect treatment with bone marrow mononuclear cells and chondrocytes leads to better macroscopic cartilage regeneration compared to microfracture in goats. Osteoarthritis Cartilage. 2013 Jul;21(7):950-6. doi: 10.1016/j.joca.2013.03.015. Epub 2013 Apr 9.</citation>
    <PMID>23583464</PMID>
  </reference>
  <reference>
    <citation>Bekkers JE, Tsuchida AI, van Rijen MH, Vonk LA, Dhert WJ, Creemers LB, Saris DB. Single-stage cell-based cartilage regeneration using a combination of chondrons and mesenchymal stromal cells: comparison with microfracture. Am J Sports Med. 2013 Sep;41(9):2158-66. doi: 10.1177/0363546513494181. Epub 2013 Jul 5.</citation>
    <PMID>23831891</PMID>
  </reference>
  <reference>
    <citation>Vonk LA, Doulabi BZ, Huang C, Helder MN, Everts V, Bank RA. Preservation of the chondrocyte's pericellular matrix improves cell-induced cartilage formation. J Cell Biochem. 2010 May;110(1):260-71. doi: 10.1002/jcb.22533.</citation>
    <PMID>20213765</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>January 13, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <results_first_submitted>May 26, 2016</results_first_submitted>
  <results_first_submitted_qc>June 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2019</results_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>D.B.F. Saris</investigator_full_name>
    <investigator_title>MD, PhD, Orthopaedic surgeon</investigator_title>
  </responsible_party>
  <keyword>IMPACT</keyword>
  <keyword>Chondrons</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Allogeneic MSCs</keyword>
  <keyword>single-stage</keyword>
  <keyword>Cartilage repair</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Foreign-Body Reaction</mesh_term>
    <mesh_term>Foreign Bodies</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment started on February 1st 2013 and was completed in September 2014</recruitment_details>
      <pre_assignment_details>Four patients were excluded based on MRI scans showing multiple cartilage defects and/ or osteochondral defects. Inclusion was continued until n = 35 was reached</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cartilage Repair Surgery</title>
          <description>All 35 patients received a single-stage cartilage repair treatment using autologous chondrons and allogeneic MSCs in a fibrin glue carrier.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cartilage Repair Surgery</title>
          <description>Single-stage cartilage repair surgery using autologous chondrons and allogeneic MSCs in a fibrin glue carrier.
Cartilage repair surgery: Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: Adverse Events</title>
        <description>Adverse events rate</description>
        <time_frame>18 months</time_frame>
        <population>All patients were monitored for the duration of the studie for inflammation and signs of a foreign body response by an independent physician using standardized clinical measures, pain assessment by numeric rating scale for pain and blood analysis including serum C-reactive protein, erythrocyte sedimentation rate and leukocyte count.</population>
        <group_list>
          <group group_id="O1">
            <title>Cartilage Repair Surgery</title>
            <description>Single-stage cartilage repair surgery in 35 patients, using autologous chondrons and allogeneic MSCs in a fibrin glue carrier.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Adverse Events</title>
          <description>Adverse events rate</description>
          <population>All patients were monitored for the duration of the studie for inflammation and signs of a foreign body response by an independent physician using standardized clinical measures, pain assessment by numeric rating scale for pain and blood analysis including serum C-reactive protein, erythrocyte sedimentation rate and leukocyte count.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement, Knee Injury and Osteoarthritis Outcome Score</title>
        <description>Clinical improvement as measured by patient reported outcome scores. The questionnaire has been developed to evaluate the symptoms and limitations for patients with osteoarthritis. The outcome of the KOOS-scale varies from 0-100, where 0 indicates the greatest possible problems and is the worst outcome and 100 indicates no problems.</description>
        <time_frame>3 and 18 months</time_frame>
        <population>Differences in clinical outcome between baseline and 3 and 12 months after surgery were tested by a repeated measures analysis of variance (ANOVA).</population>
        <group_list>
          <group group_id="O1">
            <title>Cartilage Repair Surgery</title>
            <description>To evaluate the clinical status of the patients treated with the IMPACT therapy, the included patients were asked to complete the Knee injury and Osteoarthritis Outcome Scoring (KOOS), The visual analog scale (VAS) for pain and the EuroQoL 5-Dimension Health Questionnaire (EQ5D) at baseline (before IMPACT therapy) and at 3, 6, and 12 months follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement, Knee Injury and Osteoarthritis Outcome Score</title>
          <description>Clinical improvement as measured by patient reported outcome scores. The questionnaire has been developed to evaluate the symptoms and limitations for patients with osteoarthritis. The outcome of the KOOS-scale varies from 0-100, where 0 indicates the greatest possible problems and is the worst outcome and 100 indicates no problems.</description>
          <population>Differences in clinical outcome between baseline and 3 and 12 months after surgery were tested by a repeated measures analysis of variance (ANOVA).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KOOS outcome baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS outcome 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS outcome 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A repeated-measures analysis of variance was used to test for differences in clinical outcome between baseline and 3, and 18 months after surgery.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A repeated-measures analysis of variance was used to test for differences in clinical outcome between baseline and 3, and 18 months after surgery.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Structural Repair</title>
        <description>To examine parameters of structural repair at one year after treatment using MRI and a second-look arthroscopy.</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Health Care Use and Costs</title>
        <description>To assess the healthcare use and costs related to the procedure as well as the health-related work leave during the study period.</description>
        <time_frame>18 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All patients were monitored for the duration of 18 months after surgery, at fixed time points (at 7 days, 6 weeks and 3,6,12 and 18 months after surgery), for inflammation and signs of a foreign body response by an independent physician (rheumatologist) using standardized clinical measures, pain assessment by numeric rating scale for pain and blood analysis including serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and leukocyte count.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cartilage Repair Surgery</title>
          <description>All 35 patients received a single-stage cartilage repair treatment using autologous chondrons and allogeneic MSCs in a fibrin glue carrier.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Post surgery (joint swelling, pain)</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Daniel Saris</name_or_title>
      <organization>UMC Utrecht</organization>
      <phone>000000000000000000</phone>
      <email>d.saris@umcutrecht.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

